This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Screening, Brief Intervention, and Referral to Treatment for Offenders (SBIRT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Prendergast, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01683643
First received: September 5, 2012
Last updated: May 9, 2017
Last verified: May 2017
  Purpose
The purpose of the study is to determine whether SBIRT is an effective intervention with inmates and to estimate the costs of providing SBIRT to this population.

Condition Intervention
Substance Use HIV Infections Behavioral: SBIRT Behavioral: Control Group

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Screening, Brief Intervention, and Referral to Treatment for Offenders

Resource links provided by NLM:


Further study details as provided by Michael Prendergast, University of California, Los Angeles:

Primary Outcome Measures:
  • A reduction in the use of drugs and alcohol [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Participation in treatment [ Time Frame: 12 months ]
  • Rearrest and incarceration [ Time Frame: 12 months ]
  • Quality of life [ Time Frame: 12 months ]
  • A reduction in HIV risk behaviors [ Time Frame: 12 months ]
  • The cost benefit of SBIRT for offenders [ Time Frame: 12 months ]

Estimated Enrollment: 800
Study Start Date: April 2012
Study Completion Date: March 31, 2017
Primary Completion Date: March 31, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SBIRT Group
Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles.
Behavioral: SBIRT
Screening, brief intervention, and referral to treatment.
Active Comparator: Control Group
Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
Behavioral: Control Group
Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.

Detailed Description:

Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based practice that has been found to be effective in reducing alcohol and illicit drug use, mainly among persons recruited in medical centers, primary care offices, emergency rooms, and colleges and universities. But SBIRT has the potential to be applicable to other populations that have, or that are at risk for, substance use problems. In particular, offenders have high prevalence of drug and alcohol use at varying levels of severity and often do not receive adequate intervention, either because of limited availability of programs, low motivation, or lack of awareness of the consequences of their substance use.

The scientific aims of the study are:

  1. Assess the effectiveness of SBIRT with offenders in terms of participation in brief intervention (if so indicated) and enrollment in treatment (if so indicated).
  2. Assess the effectiveness of SBIRT with offenders in terms of drug use, criminal activity, and criminal justice involvement at 12 months following baseline.
  3. Determine whether there are differences in acceptability, participation, and outcomes between men and women.
  4. Determine the cost of providing the SBIRT intervention with this population.

The clinical aims of the study are:

  1. To complement the use of SBIRT within Los Angeles County's substance abuse treatment system.
  2. To expand prevention and treatment options for offenders with substance abuse problems.

To our knowledge, this would be the first rigorous test of SBIRT with an offender population.

We will recruit inmates at two Los Angeles County Sheriff jail facilities, one for men and one for women (25% of total sample), and randomly assign them to the treatment (SBIRT) group (N =400) or to the control (no intervention) group (N = 400). Baseline demographic data will be collected. Subjects in both groups will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles. Twelve months after study admission, all study participants will be contacted for a follow-up interview. We will obtain records-based data on arrests and jail incarceration over the follow-up period from the Sheriff's Department and the California Department of Justice. We will also collect subject participation in publicly-funded treatment from the Substance Abuse Prevention and Control Division of the Los Angeles County Department of Health.

  Eligibility

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The sample for the study will be drawn from an offender population who are within 2-3 weeks of their release from MCJ or CRDF in Los Angeles County. In addition, subjects must be:

    • At least 18 years of age
    • English or Spanish speaking
    • Not subject to extended jail or prison sentence
    • Able to provide informed consent to participate in the study

Exclusion Criteria:

  • Study exclusion criteria:

    • Inability to provide informed consent to study participation because of cognitive impairment.
    • Inability to communicate in either English or Spanish
    • Refusal to complete Locator form for follow-up.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01683643

Locations
United States, California
University of California
Los Angeles, California, United States, 90025
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Michael Prendergast, Ph.D UCLA Integrated Substance Abuse Programs
Study Director: Jerry Cartier, M.A. UCLA Integrated Substance Abuse Programs
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Michael Prendergast, Principal Investigator, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01683643     History of Changes
Other Study ID Numbers: R01DA031879 ( US NIH Grant/Contract Award Number )
Study First Received: September 5, 2012
Last Updated: May 9, 2017

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases

ClinicalTrials.gov processed this record on June 27, 2017